New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer.
OpenAlex 토픽 ·
Medicinal Plants and Bioactive Compounds
Andrographolide Research and Applications
Flavonoids in Medical Research
Salidroside (SAL) is a natural glycoside compound with various biological activities.
APA
Bing Zhang, Yu Zhang, et al. (2026). New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer.. Bioorganic & medicinal chemistry letters, 136, 130627. https://doi.org/10.1016/j.bmcl.2026.130627
MLA
Bing Zhang, et al.. "New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer.." Bioorganic & medicinal chemistry letters, vol. 136, 2026, pp. 130627.
PMID
41861920
Abstract
Salidroside (SAL) is a natural glycoside compound with various biological activities. Recent studies have shown that SAL exhibits certain therapeutic effects on triple-negative breast cancer (TNBC). To enhance the anti-TNBC activity, 15 SAL-furoxan hybrids were designed and synthesized. The anti-proliferative activities of all target compounds against four tumor cell lines (MDA-MB-231, MCF-7, BGC-823, and A549) and a normal human cell line (MCF-10A) were evaluated using the MTT assay. A12 demonstrated the most potent inhibitory activity on MDA-MB-231 cells (IC₅₀ = 14 nM), and lower toxicity compared to DOX (SI = IC/IC: 129.57 vs 1.01). Further research indicated that the anti-tumor mechanism of A12 involves the high amount of NO released in MDA-MB-231 cells and thereby induction of cells apoptosis.
MeSH Terms
Humans; Glucosides; Phenols; Triple Negative Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Apoptosis; Structure-Activity Relationship; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Molecular Structure
같은 제1저자의 인용 많은 논문 (5)
- Deliberately Staged Combined Endovascular Embolization and Subsequent Microsurgery Resection for the Treatment of Cerebral Arteriovenous Malformations.
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.
- A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
- Sanguinarine Antagonizes NSCLC Through PPARG-Mediated PI3K/AKT Suppression and Autophagic Apoptosis.
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.